Hodgkin-lymphomás betegeink kezelése során szerzett tapasztalatok az utóbbi évtizedben

Translated title of the contribution: Our experiences with treating patients of Hodgkin's disease in the last decade

Zsófia Simon, Katalin Keresztes, Zsófia Miltényi, Zsuzsanna Ress, László Váróczy, Györgyi Vadász, L. Gergely, A. Illés

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Introduction: Recently, in the diagnostics and treatment of Hodgkin's disease significant developments have occurred. Aim: To sumarize the clinical and histological data of patients with Hodgkin's disease, treated at the 3rd Department of Internal Medicine, University of Debrecen between 1995-2004. In 2006 January, the mean follow-up was 69 (12-132) months. Methods: Patients data was analyzed by using SPSS statistical software. Results: The mean age of the 163 patients at the diagnosis was 36 years (14-75), with bimodal age distribution, the most frequent disease subtype was mixed-cell Hodgkin's disease (48.5%). 41.1% of the patients was at early stage, 15.7% had the worst prognosis, while 28.8% had bulky tumor. 7 patients had radioterapy, 63 had chemotherapy, while at 92 patients combined modality treatment was used. 61.6% of radiotherapies were involved field, 61 patients received cyclophosphamide, vincristine, procarbazine, prednisolone, adriamycine, bleomycine, vinblastine, 87 adriamycine, bleomycine, vinblastine, 7 had other chemotherapies. As the response to the primary treatment 146 complete, 10 partial remission occured, while 6 patients showed no response. 10 patients with partial remission and 5 non-responders were continually treated. 27 patients with complete remission had relapse, while 15 had high dose treatment with autologous peripheral stem cell transplantation. During the follow-up 18 patients died, 11 due to the lymphoma progression, or as the result of treatment, 6 had secondary malignancies, 1 due to other reasons. The 10-year prognosed overall survival was 83% (in details: early, advanced, favourable vs. unfavourable: 100% vs. 87.8%, 88.9% vs. 41.6%), the event free survival was 70% (82.6% vs. 70.8%, 64.5% vs. 0%). Conclusion: The treatment results of our Hodgkin's disease patients improved, additionally we showed that patients with early stage favourable disease the treatment toxicity should be reduced, while patients with advanced, unfavourable prognosis (10% of all patients) agressive primary treatment should be used even with more severe side effects and complications.

Original languageHungarian
Pages (from-to)675-682
Number of pages8
JournalOrvosi Hetilap
Volume148
Issue number15
DOIs
Publication statusPublished - Apr 15 2007

Fingerprint

Hodgkin Disease
Vinblastine
Therapeutics
Procarbazine
Peripheral Blood Stem Cell Transplantation
Drug Therapy
Age Distribution
Vincristine
Internal Medicine
Prednisolone
Cyclophosphamide
Disease-Free Survival
Lymphoma
Neoplasms
Radiotherapy
Software

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Simon, Z., Keresztes, K., Miltényi, Z., Ress, Z., Váróczy, L., Vadász, G., ... Illés, A. (2007). Hodgkin-lymphomás betegeink kezelése során szerzett tapasztalatok az utóbbi évtizedben. Orvosi Hetilap, 148(15), 675-682. https://doi.org/10.1556/OH.2007.27884

Hodgkin-lymphomás betegeink kezelése során szerzett tapasztalatok az utóbbi évtizedben. / Simon, Zsófia; Keresztes, Katalin; Miltényi, Zsófia; Ress, Zsuzsanna; Váróczy, László; Vadász, Györgyi; Gergely, L.; Illés, A.

In: Orvosi Hetilap, Vol. 148, No. 15, 15.04.2007, p. 675-682.

Research output: Contribution to journalArticle

Simon, Z, Keresztes, K, Miltényi, Z, Ress, Z, Váróczy, L, Vadász, G, Gergely, L & Illés, A 2007, 'Hodgkin-lymphomás betegeink kezelése során szerzett tapasztalatok az utóbbi évtizedben', Orvosi Hetilap, vol. 148, no. 15, pp. 675-682. https://doi.org/10.1556/OH.2007.27884
Simon Z, Keresztes K, Miltényi Z, Ress Z, Váróczy L, Vadász G et al. Hodgkin-lymphomás betegeink kezelése során szerzett tapasztalatok az utóbbi évtizedben. Orvosi Hetilap. 2007 Apr 15;148(15):675-682. https://doi.org/10.1556/OH.2007.27884
Simon, Zsófia ; Keresztes, Katalin ; Miltényi, Zsófia ; Ress, Zsuzsanna ; Váróczy, László ; Vadász, Györgyi ; Gergely, L. ; Illés, A. / Hodgkin-lymphomás betegeink kezelése során szerzett tapasztalatok az utóbbi évtizedben. In: Orvosi Hetilap. 2007 ; Vol. 148, No. 15. pp. 675-682.
@article{827af87467a3451aa13ecae449840895,
title = "Hodgkin-lymphom{\'a}s betegeink kezel{\'e}se sor{\'a}n szerzett tapasztalatok az ut{\'o}bbi {\'e}vtizedben",
abstract = "Introduction: Recently, in the diagnostics and treatment of Hodgkin's disease significant developments have occurred. Aim: To sumarize the clinical and histological data of patients with Hodgkin's disease, treated at the 3rd Department of Internal Medicine, University of Debrecen between 1995-2004. In 2006 January, the mean follow-up was 69 (12-132) months. Methods: Patients data was analyzed by using SPSS statistical software. Results: The mean age of the 163 patients at the diagnosis was 36 years (14-75), with bimodal age distribution, the most frequent disease subtype was mixed-cell Hodgkin's disease (48.5{\%}). 41.1{\%} of the patients was at early stage, 15.7{\%} had the worst prognosis, while 28.8{\%} had bulky tumor. 7 patients had radioterapy, 63 had chemotherapy, while at 92 patients combined modality treatment was used. 61.6{\%} of radiotherapies were involved field, 61 patients received cyclophosphamide, vincristine, procarbazine, prednisolone, adriamycine, bleomycine, vinblastine, 87 adriamycine, bleomycine, vinblastine, 7 had other chemotherapies. As the response to the primary treatment 146 complete, 10 partial remission occured, while 6 patients showed no response. 10 patients with partial remission and 5 non-responders were continually treated. 27 patients with complete remission had relapse, while 15 had high dose treatment with autologous peripheral stem cell transplantation. During the follow-up 18 patients died, 11 due to the lymphoma progression, or as the result of treatment, 6 had secondary malignancies, 1 due to other reasons. The 10-year prognosed overall survival was 83{\%} (in details: early, advanced, favourable vs. unfavourable: 100{\%} vs. 87.8{\%}, 88.9{\%} vs. 41.6{\%}), the event free survival was 70{\%} (82.6{\%} vs. 70.8{\%}, 64.5{\%} vs. 0{\%}). Conclusion: The treatment results of our Hodgkin's disease patients improved, additionally we showed that patients with early stage favourable disease the treatment toxicity should be reduced, while patients with advanced, unfavourable prognosis (10{\%} of all patients) agressive primary treatment should be used even with more severe side effects and complications.",
keywords = "Chemotherapy, Hodgkin-lymphoma, Prognosis, Radiotherapy, Survival",
author = "Zs{\'o}fia Simon and Katalin Keresztes and Zs{\'o}fia Milt{\'e}nyi and Zsuzsanna Ress and L{\'a}szl{\'o} V{\'a}r{\'o}czy and Gy{\"o}rgyi Vad{\'a}sz and L. Gergely and A. Ill{\'e}s",
year = "2007",
month = "4",
day = "15",
doi = "10.1556/OH.2007.27884",
language = "Hungarian",
volume = "148",
pages = "675--682",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "15",

}

TY - JOUR

T1 - Hodgkin-lymphomás betegeink kezelése során szerzett tapasztalatok az utóbbi évtizedben

AU - Simon, Zsófia

AU - Keresztes, Katalin

AU - Miltényi, Zsófia

AU - Ress, Zsuzsanna

AU - Váróczy, László

AU - Vadász, Györgyi

AU - Gergely, L.

AU - Illés, A.

PY - 2007/4/15

Y1 - 2007/4/15

N2 - Introduction: Recently, in the diagnostics and treatment of Hodgkin's disease significant developments have occurred. Aim: To sumarize the clinical and histological data of patients with Hodgkin's disease, treated at the 3rd Department of Internal Medicine, University of Debrecen between 1995-2004. In 2006 January, the mean follow-up was 69 (12-132) months. Methods: Patients data was analyzed by using SPSS statistical software. Results: The mean age of the 163 patients at the diagnosis was 36 years (14-75), with bimodal age distribution, the most frequent disease subtype was mixed-cell Hodgkin's disease (48.5%). 41.1% of the patients was at early stage, 15.7% had the worst prognosis, while 28.8% had bulky tumor. 7 patients had radioterapy, 63 had chemotherapy, while at 92 patients combined modality treatment was used. 61.6% of radiotherapies were involved field, 61 patients received cyclophosphamide, vincristine, procarbazine, prednisolone, adriamycine, bleomycine, vinblastine, 87 adriamycine, bleomycine, vinblastine, 7 had other chemotherapies. As the response to the primary treatment 146 complete, 10 partial remission occured, while 6 patients showed no response. 10 patients with partial remission and 5 non-responders were continually treated. 27 patients with complete remission had relapse, while 15 had high dose treatment with autologous peripheral stem cell transplantation. During the follow-up 18 patients died, 11 due to the lymphoma progression, or as the result of treatment, 6 had secondary malignancies, 1 due to other reasons. The 10-year prognosed overall survival was 83% (in details: early, advanced, favourable vs. unfavourable: 100% vs. 87.8%, 88.9% vs. 41.6%), the event free survival was 70% (82.6% vs. 70.8%, 64.5% vs. 0%). Conclusion: The treatment results of our Hodgkin's disease patients improved, additionally we showed that patients with early stage favourable disease the treatment toxicity should be reduced, while patients with advanced, unfavourable prognosis (10% of all patients) agressive primary treatment should be used even with more severe side effects and complications.

AB - Introduction: Recently, in the diagnostics and treatment of Hodgkin's disease significant developments have occurred. Aim: To sumarize the clinical and histological data of patients with Hodgkin's disease, treated at the 3rd Department of Internal Medicine, University of Debrecen between 1995-2004. In 2006 January, the mean follow-up was 69 (12-132) months. Methods: Patients data was analyzed by using SPSS statistical software. Results: The mean age of the 163 patients at the diagnosis was 36 years (14-75), with bimodal age distribution, the most frequent disease subtype was mixed-cell Hodgkin's disease (48.5%). 41.1% of the patients was at early stage, 15.7% had the worst prognosis, while 28.8% had bulky tumor. 7 patients had radioterapy, 63 had chemotherapy, while at 92 patients combined modality treatment was used. 61.6% of radiotherapies were involved field, 61 patients received cyclophosphamide, vincristine, procarbazine, prednisolone, adriamycine, bleomycine, vinblastine, 87 adriamycine, bleomycine, vinblastine, 7 had other chemotherapies. As the response to the primary treatment 146 complete, 10 partial remission occured, while 6 patients showed no response. 10 patients with partial remission and 5 non-responders were continually treated. 27 patients with complete remission had relapse, while 15 had high dose treatment with autologous peripheral stem cell transplantation. During the follow-up 18 patients died, 11 due to the lymphoma progression, or as the result of treatment, 6 had secondary malignancies, 1 due to other reasons. The 10-year prognosed overall survival was 83% (in details: early, advanced, favourable vs. unfavourable: 100% vs. 87.8%, 88.9% vs. 41.6%), the event free survival was 70% (82.6% vs. 70.8%, 64.5% vs. 0%). Conclusion: The treatment results of our Hodgkin's disease patients improved, additionally we showed that patients with early stage favourable disease the treatment toxicity should be reduced, while patients with advanced, unfavourable prognosis (10% of all patients) agressive primary treatment should be used even with more severe side effects and complications.

KW - Chemotherapy

KW - Hodgkin-lymphoma

KW - Prognosis

KW - Radiotherapy

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=34547398504&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34547398504&partnerID=8YFLogxK

U2 - 10.1556/OH.2007.27884

DO - 10.1556/OH.2007.27884

M3 - Article

C2 - 17416575

AN - SCOPUS:34547398504

VL - 148

SP - 675

EP - 682

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 15

ER -